KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Free Cash Flow (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Free Cash Flow data on record, last reported at -$19.9 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 38.23% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$113.9 million, up 46.33%, while the annual FY2025 figure was -$113.9 million, 46.33% up from the prior year.
  • Free Cash Flow reached -$19.9 million in Q4 2025 per PACB's latest filing, down from -$18.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$17.3 million in Q2 2021 and bottomed at -$98.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$49.6 million, with a median of -$45.1 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 273.72% in 2022, then skyrocketed 58.32% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$34.6 million in 2021, then plummeted by 89.49% to -$65.5 million in 2022, then rose by 8.99% to -$59.6 million in 2023, then surged by 45.85% to -$32.3 million in 2024, then soared by 38.23% to -$19.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$19.9 million in Q4 2025, -$18.6 million in Q3 2025, and -$29.9 million in Q2 2025.